Page 1 | Search Results | Blood Advances | American Society of Hematology

1-12 of 12

Sort by

Sort Order Select

Journal Articles

Impact of Measurable Residual Disease Clearance Kinetics in Patients with AML Undergoing Intensive Chemotherapy

Wei Ying Jen, Koji Sasaki, Farhad Ravandi, Tapan M. Kadia, Sa A. Wang, Wei Wang, Sanam Loghavi, Naval G. Daver, Courtney D. DiNardo, Ghayas C. Issa, Hussein A. Abbas, Cedric Nasnas, Alex Bataller, Samuel Urrutia, Omer S. Karrar, Sherry A Pierce, Hagop M Kantarjian, Nicholas J. Short

Blood Adv bloodadvances.2024013826.

https://doi.org/10.1182/bloodadvances.2024013826

Published: 2024

Includes: Supplemental data

Journal Articles

Therapy-related chronic myelomonocytic leukemia does not have the high-risk features of a therapy-related neoplasm

Alex Bataller, Georgina Gener-Ricos, Emmanuel Almanza-Huante, Kelly S. Chien, Samuel Urrutia, Alexandre Bazinet, Juan Jose Rodriguez-Sevilla, Danielle Hammond, Koji Sasaki, Koichi Takahashi, Courtney D. DiNardo, Farhad Ravandi, Gautam Borthakur, Tapan M. Kadia, Rashmi Kanagal-Shamanna, Hagop M. Kantarjian, Guillermo Garcia-Manero, Guillermo Montalban-Bravo

Blood Adv (2024) 8 (11): 2695–2706.

https://doi.org/10.1182/bloodadvances.2024012565

Published: 2024

Includes: Supplemental data

Journal Articles

Undetectable measurable residual disease is associated with improved outcomes in AML irrespective of treatment intensity

Blood Adv (2023) 7 (13): 3284–3296.

https://doi.org/10.1182/bloodadvances.2022009391

Published: 2023

Includes: Supplemental data

Journal Articles

Targeted therapy with the mutant IDH2 inhibitor enasidenib for high-risk IDH2 -mutant myelodysplastic syndrome

Blood Adv (2023) 7 (11): 2378–2387.

https://doi.org/10.1182/bloodadvances.2022008378

Published: 2023

Includes: Supplemental data

Journal Articles

Clinical outcomes associated with NPM1 mutations in patients with relapsed or refractory AML

Blood Adv (2023) 7 (6): 933–942.

https://doi.org/10.1182/bloodadvances.2022008316

Published: 2023

Includes: Supplemental data

Journal Articles

Characteristics and outcomes of patients with blastic plasmacytoid dendritic cell neoplasm treated with frontline HCVAD

Naveen Pemmaraju, Nathaniel R. Wilson, Guillermo Garcia-Manero, Koji Sasaki, Joseph D. Khoury, Nitin Jain, Gautam Borthakur, Farhad Ravandi, Naval Daver, Tapan Kadia, Courtney DiNardo, Elias Jabbour, Sherry Pierce, Muzaffar Qazilbash, Marina Konopleva, Hagop Kantarjian

Blood Adv (2022) 6 (10): 3027–3035.

https://doi.org/10.1182/bloodadvances.2021006645

Published: 2022

Includes: Supplemental data

Journal Articles

Impact of splicing mutations in acute myeloid leukemia treated with hypomethylating agents combined with venetoclax

Blood Adv (2021) 5 (8): 2173–2183.

https://doi.org/10.1182/bloodadvances.2020004173

Published: 2021

Includes: Supplemental data

Journal Articles

Prognostic value of measurable residual disease after venetoclax and decitabine in acute myeloid leukemia

Blood Adv (2021) 5 (7): 1876–1883.

https://doi.org/10.1182/bloodadvances.2020003717

Published: 2021

Includes: Supplemental data

Journal Articles

Outcomes of older patients with NPM1-mutated AML: current treatments and the promise of venetoclax-based regimens

Blood Adv (2020) 4 (7): 1311–1320.

https://doi.org/10.1182/bloodadvances.2019001267

Published: 2020

Includes: Supplemental data

Journal Articles

Genomic context and TP53 allele frequency define clinical outcomes in TP53 -mutated myelodysplastic syndromes

Blood Adv (2020) 4 (3): 482–495.

https://doi.org/10.1182/bloodadvances.2019001101

Published: 2020

Includes: Supplemental data

Journal Articles

NPM1 mutations define a specific subgroup of MDS and MDS/MPN patients with favorable outcomes with intensive chemotherapy

Blood Adv (2019) 3 (6): 922–933.

https://doi.org/10.1182/bloodadvances.2018026989

Published: 2019

Includes: Supplemental data

Journal Articles

Analysis of cardiovascular and arteriothrombotic adverse events in chronic-phase CML patients after frontline TKIs

Preetesh Jain, Hagop Kantarjian, Prajwal C. Boddu, Graciela M. Nogueras-González, Srdan Verstovsek, Guillermo Garcia-Manero, Gautam Borthakur, Koji Sasaki, Tapan M. Kadia, Princy Sam, Hycienth Ahaneku, Susan O’Brien, Zeev Estrov, Farhad Ravandi, Elias Jabbour, Jorge E. Cortes

Blood Adv (2019) 3 (6): 851–861.

https://doi.org/10.1182/bloodadvances.2018025874

Published: 2019

Includes: Supplemental data

NARROW

Impact of Measurable Residual Disease Clearance Kinetics in Patients with AML Undergoing Intensive Chemotherapy

Therapy-related chronic myelomonocytic leukemia does not have the high-risk features of a therapy-related neoplasm

Undetectable measurable residual disease is associated with improved outcomes in AML irrespective of treatment intensity

Targeted therapy with the mutant IDH2 inhibitor enasidenib for high-risk IDH2 -mutant myelodysplastic syndrome

Clinical outcomes associated with NPM1 mutations in patients with relapsed or refractory AML

Characteristics and outcomes of patients with blastic plasmacytoid dendritic cell neoplasm treated with frontline HCVAD

Impact of splicing mutations in acute myeloid leukemia treated with hypomethylating agents combined with venetoclax

Prognostic value of measurable residual disease after venetoclax and decitabine in acute myeloid leukemia

Outcomes of older patients with NPM1-mutated AML: current treatments and the promise of venetoclax-based regimens

Genomic context and TP53 allele frequency define clinical outcomes in TP53 -mutated myelodysplastic syndromes

NPM1 mutations define a specific subgroup of MDS and MDS/MPN patients with favorable outcomes with intensive chemotherapy

Analysis of cardiovascular and arteriothrombotic adverse events in chronic-phase CML patients after frontline TKIs

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only